Obicetrapib
Obicetrapib is an experimental CETP inhibitor that is intended to treat dyslipidemia. In a clinical trial, as an add-on to statins, compared with placebo, it decreased concentrations of LDL-C, apolipoprotein B and non-high-density lipoprotein cholesterol , and increased HDL-C concentration. As of 2023, it is in a Phase III trial.